Skip to main
  2. Stocks
  3. Reata Pharmaceuticals
RETA

Buy Reata Pharmaceuticals (RETA) Stock

See RETA stock price and Buy/Sell Reata Pharmaceuticals. Discuss news and analysts' price predictions with the investor community.
Start investing

Invest in RETA

Order type
Invest in
Amount
Market price$48.87
Estimated quantity0.00
Sign up to buy
RETA

Reata Pharmaceuticals (RETA)

—

About Reata Pharmaceuticals (RETA)

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wi...Read more
Market Cap
$1.8B
1 Year High
$50.99
Volume
893.28k
1 Year Low
$18.47
Price to Earnings Ratio
—
Open
$48.89
Dividend Rate
—
High
$50.99
Dividend Yield
—
Low
$48.24

Community

People who own or watch RETA stock

Reata Pharmaceuticals Price Targets

What analysts think RETA stock price will be.
$48.87
$54.20
10.9% Upside
$17$57

Reata Pharmaceuticals Stock Rating

What analysts recommend for RETA stock, on a scale from 1(buy) to 5(sell).
Buy
70% Strong Buy
10% Buy
20% Hold
0% Sell
0% Strong Sell

Reata Pharmaceuticals Stock Earnings

The value each RETA share was expected to gain vs. the value that each RETA share actually gained.
Expected
Actual

Latest news

View all
Reata Pharmaceuticals, Inc. (RETA) Soars 6.3%: Is Further Upside Left in the Stock?
Zacks Investment Research •

Frequently Asked Questions (FAQ)

As of Feb 03, 2023, the market cap for RETA stock is $1.8B

The 52-week high for RETA stock is $50.99. The current RETA stock price $48.87 is 4.16% below its 52-week high

The 52-week low for RETA stock is $18.47. The current RETA stock price $48.87 has increased 62.21% from its 52-week low

No, the RETA stock does not pay dividends to its shareholders

The target price for RETA stock is $54.20 based on the average of what a group of analyst think RETA stock could be worth at a future date. This is not a prediction by Public.com

How to buy RETA stock on Public

1

Sign up for a brokerage account on Public

It’s easy to get started. You can sign up for an account directly on our website or by downloading the Public app for iOS or Android.

2

Add funds to your Public account

There are multiple ways to fund your Public account—from linking a bank account to making a deposit with a debit card or wire transfer.

3

Choose how much you'd like to invest in RETA stock

Navigate to the Explore page. Then, type RETA into the search bar. When you see RETA stock appear in the results, tap it to open up the purchase screen.

4

Manage your investments in one place

You can find your newly purchased RETA stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, and alternative assets.

Buy Reata Pharmaceuticals (RETA) Stock

See RETA stock price and Buy/Sell Reata Pharmaceuticals. Discuss news and analysts' price predictions with the investor community.
Start investing

Invest in RETA

Order type
Invest in
Amount
Market price$48.87
Estimated quantity0.00
Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Products
Contact Us
Check the background of this firm on FINRA’s BrokerCheck.
Open to the Public Investing, Inc. Customer Relationship Summary

© Copyright 2023 Public Holdings, Inc. All Rights Reserved.

Market data powered by Xignite.

Brokerage services for US-listed, registered securities are offered to self-directed customers by Open to the Public Investing, Inc. (“Open to the Public Investing”), a registered broker-dealer and member of FINRA & SIPC. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings, Inc. (“Public Holdings”). This is not an offer, solicitation of an offer, or advice to buy or sell securities or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured. Apex Clearing Corporation, our clearing firm, has additional insurance coverage in excess of the regular SIPC limits. Additional information can be found here

Brokerage services for alternative assets available on Public are offered by Dalmore Group, LLC (“Dalmore”), member of FINRA & SIPC. “Alternative assets,” as the term is used at Public, are equity securities that have been issued pursuant to Regulation A of the Securities Act of 1933 (as amended) (“Regulation A”). This content is not investment advice. These investments are speculative, involve substantial risks (including illiquidity and loss of principal), and are not FDIC or SIPC insured. Alternative Assets purchased on the Public platform are not held in an Open to the Public Investing brokerage account and are self-custodied by the purchaser. The issuers of these securities may be an affiliate of Public, and Public (or an affiliate) may earn fees when you purchase or sell Alternative Assets. For more information on risks and conflicts of interest, see these disclosures. An affiliate of Public may be “testing the waters” and considering making an offering of securities under Tier 2 of Regulation A. No money or other consideration is being solicited and, if sent in response, will not be accepted. No offer to buy securities can be accepted, and no part of the purchase price can be received, until an offering statement filed with the SEC has been qualified by the SEC. Any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of acceptance given after the date of qualification by the SEC or as stated in the offering materials relating to an investment opportunity, as applicable. An indication of interest to purchase securities involves no obligation or commitment of any kind.

Cryptocurrency execution and custody services are provided by Apex Crypto LLC (NMLS ID 1828849) through a software licensing agreement between Apex Crypto LLC and Public Crypto LLC. Apex Crypto is not a registered broker-dealer or a member of SIPC or FINRA. Cryptocurrencies are not securities and are not FDIC or SIPC insured. Apex Crypto is licensed to engage in virtual currency business activity by the New York State Department of Financial Services. Please ensure that you fully understand the risks involved before trading: Legal Disclosures, Apex Crypto.

Dalmore and Apex Crypto, LLC are not affiliated with any of the Public Holdings subsidiaries. Commission-free trading of stocks and ETFs refers to $0 commissions for Open to the Public Investing self-directed individual cash brokerage accounts that trade the U.S.-listed, registered securities electronically during the Regular Trading Hours. Keep in mind that other fees such as regulatory fees, Premium subscription fees, commissions on trades during extended trading hours, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more.

Fractional shares are illiquid outside of Public and not transferable. For a complete explanation of conditions, restrictions and limitations associated with fractional shares, see our Fractional Share Disclosure to learn more.

All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns.

View Full Disclosures